162 related articles for article (PubMed ID: 24234332)
1. High expression of Cdc25B and low expression of 14-3-3σ is associated with the development and poor prognosis in urothelial carcinoma of bladder.
Zhang Z; Zhang G; Kong C
Tumour Biol; 2014 Mar; 35(3):2503-12. PubMed ID: 24234332
[TBL] [Abstract][Full Text] [Related]
2. Bromodomain 4 protein is a predictor of survival for urothelial carcinoma of bladder.
Yan Y; Yang FQ; Zhang HM; Li J; Li W; Wang GC; Che JP; Zheng JH; Liu M
Int J Clin Exp Pathol; 2014; 7(7):4231-8. PubMed ID: 25120803
[TBL] [Abstract][Full Text] [Related]
3. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.
Zhang Z; Zhang G; Kong C
Urol Oncol; 2013 Oct; 31(7):1222-30. PubMed ID: 22192978
[TBL] [Abstract][Full Text] [Related]
4. Argonaute 2 is up-regulated in tissues of urothelial carcinoma of bladder.
Yang FQ; Huang JH; Liu M; Yang FP; Li W; Wang GC; Che JP; Zheng JH
Int J Clin Exp Pathol; 2014; 7(1):340-7. PubMed ID: 24427355
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder.
Liu JY; Li YH; Lin HX; Liao YJ; Mai SJ; Liu ZW; Zhang ZL; Jiang LJ; Zhang JX; Kung HF; Zeng YX; Zhou FJ; Xie D
BMC Cancer; 2013 Jul; 13():349. PubMed ID: 23870412
[TBL] [Abstract][Full Text] [Related]
6. CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma.
Xue Y; Wu G; Wang X; Zou X; Zhang G; Xiao R; Yuan Y; Long D; Yang J; Wu Y; Xu H; Liu F; Liu M
Med Oncol; 2013 Mar; 30(1):406. PubMed ID: 23275123
[TBL] [Abstract][Full Text] [Related]
7. High expression of Notch ligand Jagged2 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.
Li W; Liu M; Feng Y; Huang YF; Xu YF; Che JP; Wang GC; Zheng JH
Int J Clin Exp Pathol; 2013; 6(11):2430-40. PubMed ID: 24228105
[TBL] [Abstract][Full Text] [Related]
8. CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer.
Xue YJ; Lu Q; Sun ZX
Med Oncol; 2011 Dec; 28(4):1363-72. PubMed ID: 20509007
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of Cdc25B in renal cell carcinoma is associated with decreased malignant features.
Yu XY; Zhang Z; Zhang GJ; Guo KF; Kong CZ
Asian Pac J Cancer Prev; 2012; 13(3):931-5. PubMed ID: 22631674
[TBL] [Abstract][Full Text] [Related]
10. CDC25B: relationship with angiogenesis and prognosis in non-small cell lung carcinoma.
Boldrini L; Gisfredi S; Ursino S; Lucchi M; Mussi A; Fontanini G
Hum Pathol; 2007 Oct; 38(10):1563-8. PubMed ID: 17651784
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of Sox2 expression in transurethral resection specimens in patients with T1 bladder cancer.
Ruan J; Wei B; Xu Z; Yang S; Zhou Y; Yu M; Liang J; Jin K; Huang X; Lu P; Cheng H
Med Oncol; 2013 Mar; 30(1):445. PubMed ID: 23307254
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes.
Wang Z; Trope CG; Flørenes VA; Suo Z; Nesland JM; Holm R
BMC Cancer; 2010 May; 10():233. PubMed ID: 20500813
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma.
Takemasa I; Yamamoto H; Sekimoto M; Ohue M; Noura S; Miyake Y; Matsumoto T; Aihara T; Tomita N; Tamaki Y; Sakita I; Kikkawa N; Matsuura N; Shiozaki H; Monden M
Cancer Res; 2000 Jun; 60(11):3043-50. PubMed ID: 10850455
[TBL] [Abstract][Full Text] [Related]
14. Expression of beclin 1 in bladder cancer and its clinical significance.
Liu GH; Zhong Q; Ye YL; Wang HB; Hu LJ; Qin ZK; Zeng MS; Zeng BH
Int J Biol Markers; 2013 Apr; 28(1):56-62. PubMed ID: 23125008
[TBL] [Abstract][Full Text] [Related]
15. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.
Bi J; Chen X; Zhang Y; Li B; Sun J; Shen H; Kong C
Urol Oncol; 2012 Sep; 30(5):688-94. PubMed ID: 20888270
[TBL] [Abstract][Full Text] [Related]
16. Expression of cell cycle regulators, 14-3-3σ and p53 proteins, and vimentin in canine transitional cell carcinoma of the urinary bladder.
Suárez-Bonnet A; Herráez P; Aguirre M; Suárez-Bonnet E; Andrada M; Rodríguez F; Espinosa de Los Monteros A
Urol Oncol; 2015 Jul; 33(7):332.e1-7. PubMed ID: 25979650
[TBL] [Abstract][Full Text] [Related]
17. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
[TBL] [Abstract][Full Text] [Related]
18. Binding of 14-3-3beta but not 14-3-3sigma controls the cytoplasmic localization of CDC25B: binding site preferences of 14-3-3 subtypes and the subcellular localization of CDC25B.
Uchida S; Kuma A; Ohtsubo M; Shimura M; Hirata M; Nakagama H; Matsunaga T; Ishizaka Y; Yamashita K
J Cell Sci; 2004 Jun; 117(Pt 14):3011-20. PubMed ID: 15173315
[TBL] [Abstract][Full Text] [Related]
19. PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway.
Liu JY; Qian D; He LR; Li YH; Liao YJ; Mai SJ; Tian XP; Liu YH; Zhang JX; Kung HF; Zeng YX; Zhou FJ; Xie D
Mol Cancer; 2013 Nov; 12(1):148. PubMed ID: 24268029
[TBL] [Abstract][Full Text] [Related]
20. 14-3-3sigma expression as a prognostic marker in undifferentiated nasopharyngeal carcinoma.
Chan SY; To KF; Leung SF; Yip WW; Mak MK; Chung GT; Lo KW
Oncol Rep; 2010 Oct; 24(4):949-55. PubMed ID: 20811675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
